Zimberelimab is a medication used in this trial to help the body’s immune system fight cancer cells. It works by blocking a specific protein that can stop the immune system from attacking cancer cells, allowing the immune system to better target and destroy them.

Domvanalimab is another medication in the trial that is used alongside Zimberelimab. It also helps the immune system by targeting a different protein, which can enhance the immune response against cancer cells, making the treatment more effective.

Pembrolizumab is a medication that helps the immune system recognize and attack cancer cells. It works by blocking a protein that prevents the immune system from attacking the cancer, thereby boosting the body’s natural defenses to fight the cancer.

Chemotherapy refers to the use of drugs to kill or slow the growth of cancer cells. In this trial, chemotherapy is used in combination with the other medications to enhance the overall effectiveness of the treatment against lung cancer.

Metastatic Non-Small Cell Lung Cancer – This is a type of lung cancer that begins in the cells of the lungs and has spread to other parts of the body. It is the most common form of lung cancer, accounting for about 85% of cases. The disease progresses as cancer cells grow and form tumors in the lungs, which can then metastasize to other organs such as the brain, bones, or liver. Symptoms may include persistent cough, chest pain, shortness of breath, and unexplained weight loss. As the cancer spreads, it can cause additional symptoms depending on the organs affected. The progression of the disease can vary greatly among individuals.